Nobuyuki Tanaka

Department of Urology

Websitehttps://k-ris.keio.ac.jp/html/100005795_ja.html

860 Citations
19 h-Index

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Nobuyuki Tanaka is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

24 Similar Profiles

Urinary Bladder Neoplasms Medicine & Life Sciences

Carcinoma Medicine & Life Sciences

Neoplasms Medicine & Life Sciences

Recurrence Medicine & Life Sciences

Renal Cell Carcinoma Medicine & Life Sciences

Prostatic Neoplasms Medicine & Life Sciences

Survival Medicine & Life Sciences

Platinum Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2007 2019

860 Citations
19 h-Index
69 Article
1 Short survey
1 Review article

2 Citations (Scopus)

Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma

Ito, K., Masunaga, A., Tanaka, N., Mizuno, R., Shirotake, S., Yasumizu, Y., Ito, Y., Miyazaki, Y., Hagiwara, M., Kanao, K., Mikami, S., Momma, T., Masuda, T., Nakagawa, K., Oyama, M., Asano, T. & Oya, M., 2019 Jan 1, In : Japanese Journal of Clinical Oncology. 49, 1, p. 69-76 8 p.

Research output: Contribution to journal › Article

Disease-Free Survival

L-Lactate Dehydrogenase

Neutrophils

Lymphocytes

Therapeutics

2 Citations (Scopus)

Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients

Takamatsu, K., Mizuno, R., Tanaka, N., Takeda, T., Morita, S., Matsumoto, K., Kosaka, T., Shinojima, T., Kikuchi, E., Asanuma, H., Oyama, M., Mikami, S. & Oya, M., 2019 Jan 1, In : International Journal of Clinical Oncology.

Research output: Contribution to journal › Article

Renal Cell Carcinoma

C-Reactive Protein

Blood Proteins

Therapeutics

Molecular Targeted Therapy

Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy

Kaneko, G., Shirotake, S., Nishimoto, K., Miyazaki, Y., Ito, K., Ito, Y., Hagiwara, M., Kanao, K., Nakagawa, K., Momma, T., Asano, T., Tanaka, N., Mizuno, R., Oya, M. & Oyama, M., 2019 Aug 1, In : Japanese journal of clinical oncology. 49, 8, p. 780-785 6 p.

Research output: Contribution to journal › Article

Renal Cell Carcinoma

Molecular Targeted Therapy

Therapeutics

Survival

Sirolimus

The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy

Takamatsu, K., Matsumoto, K., Shojo, K., Tanaka, N., Takeda, T., Morita, S., Kosaka, T., Mizuno, R., Shinojima, T., Kikuchi, E., Asanuma, H. & Oya, M., 2019 Jan 1, In : Urologic Oncology: Seminars and Original Investigations.

Research output: Contribution to journal › Article

Prostatectomy

Prostatic Neoplasms

Recurrence

Neoplasms

Patient Transfer

1 Citation (Scopus)

TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells

Niwa, N., Tanaka, N., Hongo, H., Miyazaki, Y., Takamatsu, K., Mizuno, R., Kikuchi, E., Mikami, S., Kosaka, T. & Oya, M., 2019 Jan 1, In : Laboratory Investigation.

Research output: Contribution to journal › Article

Epithelial-Mesenchymal Transition

Platinum

Carcinoma

Neoplasms

Cadherins